Moderna (MRNA) revenue: $1.9B
Moderna reported $1.9B of revenue for the year ended Dec 31, 2025, down 39.9% from $3.2B a year earlier.
From Moderna's filings with the SEC · Read the filing · MRNA stock page
Moderna revenue by year
#1,193 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $1.9B | -40% |
| Dec 31, 2024 | $3.2B | -53% |
| Dec 31, 2023 | $6.8B | -64% |
| Dec 31, 2022 | $19.3B | +4% |
| Dec 31, 2021 | $18.5B | – |
Revenue of similar companies
Companies in the same industry as Moderna, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Neurocrine Biosciences | $2.9B | Dec 31, 2025 |
| Exelixis | $2.3B | Jan 2, 2026 |
| Qiagen | $2.1B | Dec 31, 2025 |
| Moderna | $1.9B | Dec 31, 2025 |
| Halozyme Therapeutics | $1.4B | Dec 31, 2025 |
| BIO-TECHNE | $1.2B | Jun 30, 2026 |
| Novavax | $1.1B | Dec 31, 2025 |
Questions and answers
What is Moderna's revenue?
Moderna reported $1.9B of revenue for the year ended Dec 31, 2025, down 39.9% from $3.2B a year earlier.
Numbers as reported in Moderna's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology